Patents Assigned to MAP Pharmaceuticals, Inc.
-
Patent number: 8722699Abstract: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: October 3, 2013Date of Patent: May 13, 2014Assignee: Map Pharmaceuticals, Inc.Inventors: Jian Zhang, Robert O. Cook
-
Publication number: 20140123975Abstract: A medicament dispenser, in particular a metered dose inhaler, which is able to count the number of time the dispenser is activated and then disable the device, which then prevents any additional medicament from being dispensed. Additional embodiments include a medicament dispenser which are adapted to display either the number of activations that have occurred or the number of activations remaining.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventor: Alfred Sugianto
-
Publication number: 20140120165Abstract: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.Type: ApplicationFiled: October 2, 2013Publication date: May 1, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Libo Wu, Wiwik Watanabe, Jian Zhang
-
Patent number: 8710092Abstract: Provided herein are substituted indolo[4,3-fg]quinolines of Formula (I) and (II) where R1-R6 and R13 are as defined in the specification and pharmaceutical compositions thereof which are useful in treating, preventing, or ameliorating a variety of medical disorders such as, for example, migraine. In other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.Type: GrantFiled: December 23, 2010Date of Patent: April 29, 2014Assignee: Map Pharmaceuticals, Inc.Inventors: Jian Zhang, Robert O. Cook, Thomas A. Armer, Sergey Alexandrovich Kosarev, Dejian Xie
-
Publication number: 20140094483Abstract: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 3, 2013Publication date: April 3, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Jian Zhang, Robert O. Cook
-
Publication number: 20140086994Abstract: The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet.Type: ApplicationFiled: December 4, 2013Publication date: March 27, 2014Applicant: MAP Pharmaceuticals, Inc.Inventors: Neil Russell Foster, Hubert Leonardus Regtop, Fariba Dehghani
-
Publication number: 20140073647Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 7, 2013Publication date: March 13, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Publication number: 20140073790Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 7, 2013Publication date: March 13, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Publication number: 20140066450Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 7, 2013Publication date: March 6, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Robert O. Cook, JIAN ZHANG, THOMAS A. ARMER
-
Publication number: 20140039188Abstract: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Jian Zhang, Robert O. Cook
-
Publication number: 20140023595Abstract: An inhalation device for administering one or more sedatives via pulmonary inhalation for treating a sleep disturbance.Type: ApplicationFiled: September 12, 2013Publication date: January 23, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Robert Owen Cook, Thomas Armer
-
Publication number: 20130345253Abstract: Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B receptor and 5-HT2C receptors the using the compounds and compositions disclosed herein.Type: ApplicationFiled: June 22, 2012Publication date: December 26, 2013Applicant: MAP Pharmaceuticals, Inc.Inventors: Jian Zhang, Thomas A. Armer
-
Patent number: 8609611Abstract: The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet.Type: GrantFiled: December 14, 2011Date of Patent: December 17, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Neil Russell Foster, Hubert Leonardus Regtop, Fariba Dehghani
-
Patent number: 8604035Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: June 22, 2012Date of Patent: December 10, 2013Assignee: Map Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Patent number: 8592445Abstract: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1Breceptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2Breceptors using the compounds and compositions disclosed herein.Type: GrantFiled: June 22, 2012Date of Patent: November 26, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Jian Zhang, Robert O. Cook
-
Publication number: 20130306061Abstract: A pulmonary drug delivery device having one or more vortexing elements which impart beneficial flow characteristics to an inspiratory air flow carrying a medicament into the patient's lungs.Type: ApplicationFiled: July 26, 2013Publication date: November 21, 2013Applicant: MAP PHARMACEUTICALS, INC.Inventor: Prashant Kakade
-
Patent number: 8574630Abstract: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.Type: GrantFiled: September 20, 2011Date of Patent: November 5, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Libo Wu, Wiwik Watanabe, Jian Zhang
-
Patent number: 8555875Abstract: An inhalation device for administering one or more sedatives via pulmonary delivery for treating a sleep disturbance.Type: GrantFiled: December 21, 2009Date of Patent: October 15, 2013Assignee: Map Pharmaceuticals, Inc.Inventors: Robert Owen Cook, Thomas A Armer
-
Patent number: 8517009Abstract: A pulmonary drug delivery device having one or more vortexing elements which impart beneficial flow characteristics to an inspiratory air flow carrying a medicament into the patient's lungs.Type: GrantFiled: July 13, 2009Date of Patent: August 27, 2013Assignee: MAP Pharmaceuticals, Inc.Inventor: Prashant Kakade
-
Patent number: 8486043Abstract: Described here are unit dose containers, methods, and kits for treating asthma and other pulmonary conditions by nebulization. The unit doses of active agents are provided in a low volume formulation, which results in faster nebulization of the unit doses. The containers are also formed to minimize internal surface area so that effective re-dispersion of the active agents can be achieved while reducing adsorption to the walls of the containers.Type: GrantFiled: October 13, 2008Date of Patent: July 16, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Laxmi Iyer, Paul S. Uster